The Streptomycin Trial: The Birth of Randomized Clinical Research

• Introduction
• Chapter 1 The Pre-Trial Landscape of Tuberculosis Treatment
• Chapter 2 The Medical Research Council and the Post-War Era
• Chapter 3 Streptomycin: A Glimmer of Hope
• Chapter 4 Archie Cochrane and the Dawn of a New Idea
• Chapter 5 Forging the Protocol: Design and Debates
• Chapter 6 The Ethics of Randomization: A Revolutionary Concept
• Chapter 7 Assembling the Team: Statisticians, Clinicians, and Nurses
• Chapter 8 Patient Recruitment: Navigating a Novel Approach
• Chapter 9 The Control Group: A Controversial Necessity
• Chapter 10 Administering the Drug: Dosage and Regimen
• Chapter 11 Blinding and Bias: Safeguarding Objectivity
• Chapter 12 Data Collection: Meticulous Observation and Recording
• Chapter 13 Early Findings: Glimpses of Efficacy and Side Effects
• Chapter 14 The Statistician's Role: Interpreting the Numbers
• Chapter 15 Unveiling the Results: A Moment of Truth
• Chapter 16 The Impact on Tuberculosis Treatment
• Chapter 17 The Birth of Evidence-Based Medicine
• Chapter 18 Reactions from the Medical Community
• Chapter 19 Critiques and Controversies: Pushing Back Against the New Standard
• Chapter 20 Disseminating the Findings: Publications and Presentations
• Chapter 21 Long-Term Follow-up and Lasting Lessons
• Chapter 22 The Streptomycin Trial's Legacy in Clinical Research
• Chapter 23 From Streptomycin to Modern Drug Development
• Chapter 24 The Enduring Gold Standard: Randomized Controlled Trials Today
• Chapter 25 Reflecting on a Landmark Experiment

In the annals of medical history, few experiments have reshaped the landscape of clinical practice as profoundly as the 1948 Medical Research Council (MRC) trial on streptomycin for treating pulmonary tuberculosis. This groundbreaking study, often overlooked in popular narratives, stands as the pivotal moment when medical research transitioned from anecdotal observation and expert opinion to the rigorous, evidence-based methodology that defines modern medicine. This book delves into the fascinating story of that trial, exploring not only its meticulous design and execution but also the profound ethical and scientific dilemmas it confronted and ultimately resolved.

Prior to the streptomycin trial, the assessment of medical treatments was often a haphazard affair. Physicians relied heavily on their own experiences, case studies, and the prevailing wisdom of the time, leading to a chaotic and often ineffective approach to patient care. Treatments were adopted with little systematic proof of their efficacy, and discerning true benefit from mere coincidence or the natural course of a disease was a constant challenge. The very idea of intentionally withholding a promising new drug from some patients to evaluate its true impact was, at best, controversial and, at worst, considered unethical by many.

It was against this backdrop of uncertainty and well-intentioned but unscientific practice that a small group of visionary researchers, under the aegis of the Medical Research Council in post-war Britain, conceived of a radical new approach. With streptomycin—a newly discovered antibiotic showing immense promise against tuberculosis, a disease that ravaged populations worldwide—they saw not just a potential cure, but an unparalleled opportunity to establish a new gold standard for medical evidence. Their innovative solution was the randomized controlled trial (RCT), a methodology that would forever change how medical interventions are evaluated.

This book meticulously reconstructs the planning, conduct, and aftermath of the MRC streptomycin trial. We will explore the intellectual lineage that led to the concept of randomization, tracing the influence of figures like Archie Cochrane and the statistical insights that underpinned this revolutionary design. We will delve into the intricate challenges of forging the trial protocol, from defining patient eligibility and dosage regimens to establishing robust methods for data collection and analysis. Moreover, we will confront the profound ethical considerations inherent in randomization—the deliberate decision to assign patients by chance to either the new drug or a control group—a concept that sparked considerable debate and demanded a new framework for medical ethics.

Beyond the scientific mechanics, this narrative also illuminates the human element of the trial: the dedicated clinicians, statisticians, and nurses who brought it to life, and the patients whose participation laid the groundwork for future generations of medical progress. We will examine the immediate impact of the trial's startling results on the treatment of tuberculosis and, more broadly, its transformative influence on the entire field of clinical research. From the initial skepticism and critiques to its eventual widespread acceptance, the streptomycin trial stands as a testament to the power of scientific rigor in advancing human health.

"The Streptomycin Trial" is more than just a historical account; it is a foundational story for anyone interested in how we know what works in medicine. It is the story of how a single, carefully conceived experiment, born from intellectual curiosity and ethical conviction, not only provided a definitive answer to a pressing medical question but also irrevocably established the randomized controlled trial as the indispensable cornerstone of evidence-based medicine—the enduring gold standard for medical evidence that continues to shape drug development and patient care today.

Before the monumental streptomycin trial of 1948, the world grappled with tuberculosis, a relentless adversary that had plagued humanity for millennia. Known evocatively as "consumption" due to the dramatic weight loss it inflicted upon its victims, or the "white plague," tuberculosis was a pervasive and often fatal disease that cast a long shadow over public health and individual lives. In the 19th and early 20th centuries, it reached epidemic proportions, particularly in industrialized nations where overcrowded living conditions and poor sanitation provided fertile ground for its spread. It was an illness that transcended social strata, affecting both the urban poor and the affluent, though by 1900, improved nutrition, sanitation, and housing had begun to reduce the risk for wealthier individuals.

For centuries, tuberculosis was shrouded in mystery. Physicians lacked a true understanding of its cause, leading to a myriad of ineffective and sometimes bizarre treatments. In the Middle Ages, scrofula, a form of tuberculosis affecting the lymph nodes of the neck, was even believed to be curable by the "royal touch" of English and French monarchs. Early 19th-century remedies included cod liver oil, vinegar massages, and the inhalation of hemlock or turpentine, none of which offered any genuine relief. The disease's social impact was profound, leading to stigma, isolation, and despair for those afflicted.

A significant turning point came in 1882 when German microbiologist Robert Koch identified Mycobacterium tuberculosis as the bacterium responsible for the disease. This groundbreaking discovery, which earned him a Nobel Prize, finally provided a scientific basis for understanding tuberculosis, though it would be decades before effective treatments emerged. Koch himself, in 1890, briefly and unsuccessfully promoted "tuberculin," an extract of the bacillus, as a cure, though it later proved more valuable as a diagnostic tool.

With the understanding of its infectious nature, attention turned to prevention and containment. The early 20th century saw the rise of the "sanatorium movement." These institutions, often located in serene, elevated environments with fresh air and ample sunshine, became the predominant form of treatment for tuberculosis patients. The regimen at a sanatorium was based on Galenic principles of hygiene: strict bed rest, good nutrition, and fresh air, all believed to aid the body in fighting the disease. Patients were isolated from the general population, which, in addition to their potential for recovery, also served to limit the spread of the highly contagious illness.

While sanatoriums offered a structured environment and some patients did experience improvement, the efficacy of the "rest cure" was debatable. Many general assessments of sanatorium treatment were negative, with one 1937 report stating that its success largely depended on the patient's willingness to continue the prescribed routine after discharge. Indeed, a disheartening 76% of patients discharged from London County Council sanatoriums in 1927 were dead by 1932. By the mid-1940s, with antibiotics still undiscovered, sanatoriums were considered the only viable option to contain the spread of tuberculosis. They provided multidisciplinary care, including radiology and surgery, to aid in diagnosis and treatment.

Beyond the sanatorium, other, more invasive, interventions were sometimes employed. "Collapse therapy" was a surgical approach aimed at resting and healing tuberculous lesions by collapsing the affected lung. This was typically achieved by inducing an artificial pneumothorax, where air was injected into the space between the lung and the chest wall. The idea was to prevent the lung from expanding, thereby immobilizing it and reducing oxygen supply to inhibit the Mycobacterium tuberculosis bacterium. Other forms of collapse therapy involved surgically inserting plastic balls or polyethylene sponges to prevent lung expansion. While these procedures could sometimes lead to clinical improvement, they were often a last resort for desperate cases and carried significant risks.

Chemotherapy, as we understand it today, was virtually nonexistent for tuberculosis before the mid-22th century. The early 20th century saw some experimentation with heavy metals, most notably gold compounds. Based on Robert Koch's initial, albeit misleading, findings that gold cyanide was effective against M. tuberculosis in cultures (though not in animals), gold therapy gained traction, particularly in Denmark in the mid-1920s. A Danish physician, Holger Møllgaard, popularized a gold compound called sanocrysin in 1925, and initial reports from physicians were enthusiastically in its favor, despite its notable toxicity.

However, the enthusiasm for gold therapy was short-lived. Despite the initial claims, experimental evidence consistently showed negative results. Difficulties in designing interpretable clinical studies were often ignored, allowing for biased interpretations that favored the treatment. The MRC's 1948 report on streptomycin explicitly cited the "exaggerated claims made for gold treatment, persisting over 15 years," as a "spectacular example" of errors in chemotherapeutic trials for tuberculosis. Indeed, a properly planned and controlled clinical trial conducted in the United States in 1931 yielded wholly adverse results, effectively sounding the death knell for gold therapy in America. By the mid-1930s, even in Europe where it had been widely used, interest in gold therapy waned, and it vanished from tuberculosis treatment, leaving no better alternative in its wake.

The pre-antibiotic era for tuberculosis was thus characterized by a profound sense of desperation and a landscape of treatments that, at best, offered supportive care and, at worst, were ineffective, toxic, or both. The prevailing medical practice relied heavily on observational data, individual physician experience, and a general lack of systematic, controlled evaluation. The notion of a robust, objective assessment of a treatment's true efficacy was still in its nascent stages, making the forthcoming streptomycin trial a truly revolutionary endeavor in a world longing for genuine medical solutions.